A group of more than 100 experts from more than 15 countries wrote an editorial in the medical journal Blood, to call attention to the impact of exorbitant drug prices on patients.
Focusing on their area of expertise in chronic myeloid leukemia (CML) — a rare form of cancer affecting white blood cells – the . . . → Read More: Life-saving drugs, lethal prices
(CNN) — Angelina Jolie, when writing about her preventive double mastectomy, did not discuss how much her surgeries cost, but she did mention that many women would not be able to afford the $3,000 to $4,000 test that led her to make the decision. What she failed to say was why the test costs . . . → Read More: Why Jolie’s cancer test costs so much
“Angelina Jolie and the One Percent” was originally published in Scientific American on May 20th, 2013.
After learning that she had inherited a mutation on one of the so-called breast cancer genes, actress Angelina Jolie decided to have a double mastectomy to reduce her risk of developing breast cancer. She also plans to have her . . . → Read More: Angelina Jolie and the One Percent
In a much-tweeted cover story for the New York Times Magazine, Peggy Orenstein recently wrote that she once believed a mammogram saved her life. Sixteen years later, after dealing with breast cancer round two, she says she now wonders whether that first mammogram mattered at all. “Would the outcome have been the same,” she writes in Our Feel-Good War on . . . → Read More: The Mammography Debate: To Screen or Not to Screen?
Angelina Jolie’s op-ed in The New York Times was big news. Jolie shared her family history of cancer, her own genetic mutation, and her choice to have prophylactic surgery– agonizing decisions faced by other high risk women.
Actress Angelina Jolie leaves Lancaster House after attending the G8 Foreign Ministers’ conference on April 11, . . . → Read More: Celebrity Breasts and Corporate Gene Patents
Barbara Brenner (1951-2013)
Barbara Brenner was 41 when she was first diagnosed with breast cancer, a diagnosis that led the lawyer and activist to join the board of Breast Cancer Action, a grassroots advocacy organization in San Francisco started by women with breast cancer. A year later, she became the organization’s first full-time executive director. . . . → Read More: In Honor and Memory of Barbara Brenner
I’ve been spending much of my time working with the Breast Cancer Consortium to develop plans, projects, and analyses. One of my roles is to edit the Quarterly newsletter, which has just been released.
Table of Contents The Breast Cancer Consortium, Gathering Momentum! “Our Feel-Good War on Breast Cancer” Patients, Patents, and Profits “Cancer . . . → Read More: Breast Cancer Consortium Quarterly, Second Issue
Peggy Orenstein’s April 25, 2013 article–the cover story for this Week’ s New York Times’ Magazine, offers an in-depth look at breast cancer in the United States. The 9-page essay– called “Our Feel-Good War on Breast Cancer” — is well worth the read, highlighting key issues in breast cancer awareness campaigns, . . . → Read More: “Our Feel-Good War on Breast Cancer”
When the Human Genome Project started in 1990 there were fewer than 100 genes associated with human diseases. The first genetic mutation (for Huntington’s disease) was identified in 1986, just a few years before the Project started. After more than a decade of technological innovation and about $3.8 billion, a team of scientists across more than forty research sites succeeded . . . → Read More: Patients, Patents, and Profits in a Genomic Age
I get public relations pitches every day about the latest breast cancer fill-in-the-blank. I usually delete them as soon as they come in, but last week I lingered on one longer than usual. The pitch said that Dr. Allen Gabriel and The Pink Lemonade Project, along with Alaska Airlines and Starbucks, were inviting me . . . → Read More: Rights or Rhetoric? Breast reconstruction and the yet-to-be-tapped market of breast cancer survivors